Show simple item record

Expression of Mo3e antigen by cultured human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA) and related pharmacological inducers of protein kinase C

dc.contributor.authorTrochelman, R. Douglasen_US
dc.contributor.authorWeiss, Stephen J.en_US
dc.contributor.authorRegiani, Sandraen_US
dc.contributor.authorLiu, David Y.en_US
dc.contributor.authorTodd, Robert F. IIIen_US
dc.date.accessioned2006-04-07T20:22:15Z
dc.date.available2006-04-07T20:22:15Z
dc.date.issued1988-03en_US
dc.identifier.citationTrochelman, R. Douglas, Weiss, Stephen J., Regiani, Sandra, Liu, David Y., Todd, III, Robert F. (1988/03)."Expression of Mo3e antigen by cultured human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA) and related pharmacological inducers of protein kinase C." Cellular Immunology 112(1): 89-103. <http://hdl.handle.net/2027.42/27376>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6WCF-4F8K2VW-98/2/6173a7972ff3045dbc8319722292b805en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27376
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3345569&dopt=citationen_US
dc.description.abstractMo3e is a protease-sensitive membrane antigen (p75,50) selectively expressed by human monocytic cells (monocytes and U-937 cells) stimulated in vitro by exposure to a variety of activating factors, including phorbol diester compounds, bacterial lipopolysaccharide (LPS), and muramyl dipeptide (MDP) (R. F. Todd et al., J. Immunol. 135, 3869, 1985). Here we report that primary and multiply-passaged cultures of HUVEC also express the Mo3e determinant after stimulation by phorbol myristate acetate (PMA) and related inducers of protein kinase C. As measured in a radioimmunoassay of anti-Mo3e antibody binding to monolayer cultures of HUVEC, unstimulated cells bore little if any Mo3e. After culture for 4-120 hr in medium containing PMA, 4[beta]-phorbol dibutyrate, 4[beta]-phorbol didecanoate, or mezerein (each at a conentration of 81 nM), or 1-oleoyl-2-acetoyl-sn-3-glycerol (1 mM), HUVEC were found to selectively express the Mo3e determinant. The magnitude of expression was dependent upon the concentration of the stimulus, maximal by 24 hr, and inhibited by cycloheximide. The combination of PMA and the calcium ionophore, ionomycin, had an additive or synergistic effect on HUVEC Mo3e expression. The biologically inactive phorbol compounds 4[beta]-phorbol and 4[alpha]-phorbol didecanoate failed to stimulate Mo3e expression. Also inactive as inducers of HUVEC Mo3e expression were crude lymphokine and monokine supernatants, recombinant human lymphokines (interferon-[gamma] and interleukin-2), recombinant human monokines (interleukin-1 and tumor necrosis factor), bacterial cell wall products including LPS and MDP, pharmacologic agents that increase intracellular cyclic adenosine monophosphate (prostaglandin E2, cholera toxin, theophylline, isoproterenol and isobutylmethylxanthine), lectins (Con A and PHA), and heparin. These results indicate that Mo3e is an inducible plasma membrane antigen of not only mononuclear phagocytes but also cultured HUVEC.en_US
dc.format.extent1158131 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleExpression of Mo3e antigen by cultured human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA) and related pharmacological inducers of protein kinase Cen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumSimpson Memorial Research Institute, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USAen_US
dc.contributor.affiliationumSimpson Memorial Research Institute, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USAen_US
dc.contributor.affiliationumSimpson Memorial Research Institute, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USAen_US
dc.contributor.affiliationumSimpson Memorial Research Institute, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USAen_US
dc.contributor.affiliationotherCetus Corporation, Department of Immunology, Palo Alto, California 94303, USAen_US
dc.identifier.pmid3345569en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27376/1/0000404.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0008-8749(88)90278-Xen_US
dc.identifier.sourceCellular Immunologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.